Pharmacology & Therapeutics

Article	Citations
Editorial Board	351
Adenosine receptor signalling as a driver of pulmonary fibrosis	345
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	318
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	271
The role of macrophages in asthma-related fibrosis and remodelling	229
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	227
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	207
Potential neonatal toxicity of new psychoactive substances	205
Unfolded protein responses: Dynamic machinery in wound healing	199
Inflammation, lipids, and pain in vulvar disease	186
Matrikines in the skin: Origin, effects, and therapeutic potential	183
Treatment strategies for leptomeningeal disease in patients with breast cancer	172
Endothelial dysfunction as a complication of anti-cancer therapy	153
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	143
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	143
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	140
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	136
Non-canonical G protein signaling	134
Collateral lethality: A unique type of synthetic lethality in cancers	129
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	128
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	119
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	117
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	115
Contribution of non-selective membrane channels and receptors in epilepsy	114
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	114

Management of drug-resistant hypertension as a heterogeneous disorder	106
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	104
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	100
Cell-based therapies for vascular regeneration: Past, present and future	100
TAAR1 as an emerging target for the treatment of psychiatric disorders	99
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	97
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	94
TLR4 biased small molecule modulators	93
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	92
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	91
Boron in cancer therapeutics: An overview	91
Dysregulation of metabolic pathways in pulmonary fibrosis	91
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	91
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	90
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	89
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	88
Review: Sex-related differences in the treatment of cardiac arrhythmia	87
Editorial Board	85
Pharmacological treatment of cardiogenic shock – A state of the art review	84
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	81
Natural products that alleviate depression: The putative role of autophagy	81
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	79
PGRMC1: An enigmatic heme-binding protein	78
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	78
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	78
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	74
Bispecific antibodies for the treatment of neuroblastoma	73
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	72
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	71
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	69
Wnt signaling: A prospective therapeutic target for chronic pain	69
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	67
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	66
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	66
DNA methylation in cell plasticity and malignant transformation in liver diseases	66
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	65
Stabilizing the neural barrier – A novel approach in pain therapy	65
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	62
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	62
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	62
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	62
Advances in pathogenesis and therapeutic strategies for osteoporosis	61
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain	60
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	59
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	59
Regulation of feeding and therapeutic application of bioactive peptides	59
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	59
The role of drug-metabolizing enzymes in synthetic lethality of cancer	58
Therapeutic targeting of DNA methylation alterations in cancer	57
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	57

Optimizing drug therapies in cardiac amyloidosis	56
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	56
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	56
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	55
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	55
Recent advances in riboflavin transporter RFVT and its genetic disease	54
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	54
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	53
Organic anion transporters in remote sensing and organ crosstalk	52
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	52
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	52
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	52
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	51
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects	51
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	51
Editorial Board	51
Pharmacological potential of cyclic nucleotide signaling in immunity	51
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	51
CDNF and ER stress: Pharmacology and therapeutic possibilities	50
MicroRNAs in drug addiction: Current status and future perspectives	49
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	48
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	48
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	48
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	47
Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo	47
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	47
Emerging methods for and novel insights gained by absolute quantification of mitochondrial DNA copy number and its clinical applications	47
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	46
Editorial Board	46
Corrigendum to “Drug discovery through biophysical techniques: Methods and applications” [pharmacology and therapeutics volume 277 (2026) 108947]	46
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	46
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	45
The role and participation of immune cells in the endometrial tumor microenvironment	45
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	44
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	43
Oxidative stress and antioxidant therapeutic mechanisms	43
Molecular mechanisms of ferroptosis and their involvement in brain diseases	43
G protein-coupled estrogen receptor biased signaling in health and disease	43
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	42
Exploring the landscape of post-translational modification in drug discovery	42
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	42
Modulation of hyaluronan signaling as a therapeutic target in human disease	42
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	42
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	41
Editorial Board	41
Potential targeting of the tumor microenvironment to improve cancer virotherapy	41
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	40
Platelet lipid metabolism in vascular thrombo-inflammation	40
Understanding the molecular bridges between the drugs and immune cell	40
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	40
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	39
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	39
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	39
Targeting cell cycle checkpoints for glioma therapy	39
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	38
From bench to clinic: Emerging therapies for corneal scarring	38
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	38
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	38
Editorial Board	37
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	37
Early life adversities, psychopathologies and novel pharmacological strategies	37
Prolactin and pain of endometriosis	37
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	36
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	36
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	36
The antidepressant actions of ketamine and its enantiomers	35
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	35
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	35
Plant-derived nanovesicles and therapeutic application	35
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	34
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	34
Anti-cancer activity of sustained release capsaicin formulations	33
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	33
Editorial Board	33
Biased signaling in drug discovery and precision medicine	33
Gene and stem cell therapy for inherited cardiac arrhythmias	33
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	33
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	33
Editorial Board	33
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	32

GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	32
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	32
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	32
Bile acids and neurological disease	32
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	32
Microvascular basis of cognitive impairment in type 1 diabetes	31
Editorial Board	31
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	31
Spotlight on plasticity-related genes: Current insights in health and disease	31
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	31
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	31
Retina-directed gene therapy: Achievements and remaining challenges	31
Targeting immunoproteasome in neurodegeneration: A glance to the future	31
Treatment of overdose in the synthetic opioid era	31
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	31